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Abstract
Objectives: The Zwolle risk score (ZRS) has been considered to be a useful tool for the systematic evaluation of patients
for early discharge after primary percutaneous coronary intervention (PCI). Therefore, aim of this study was to evaluate
the clinical utility of ZRS for the same-day discharge strategy after primary PCI at a tertiary care cardiac center of
Karachi, Pakistan.
Methods: This study was conducted at a tertiary care cardiac center between August 2019 and July 2020. Patients
discharged within 24 h (same-day) of the primary PCI procedure were included. Patients were stratiﬁed as high- and lowrisk based on ZRS score; low-risk (≤3) and high-risk (≥4). All patients were followed during 30-days post-procedure
period for major adverse cardiac events (MACE).
Results: Out of 487 patients, 83.2% (405) were male and mean age was 54.6 ± 10.87 years. Mean ZRS was 2.34 ± 1.64
with 16.0% (78) patients in high-risk (≥4) group. 30-days MACE rate was observed to be 5.3% (26) with signiﬁcantly
higher rate among high-risk patients as compared to low-risk patients 12.8% (10) vs. 3.9% (16); p ¼ 0.004 respectively
with OR of 3.61 [1.57e8.29]. The area under the curve (AUC) of ZRS for prediction of 30-day MACE was 0.67 [95% CI:
0.58e0.77], ZRS ≥4 had sensitivity of 38.5% and speciﬁcity of 85.2% with AUC of 0.62 [95% CI: 0.50e0.74] for prediction
of 30-day MACE.
Conclusion: ZRS showed moderate discriminating potential in identifying patients with high-risk of MACE at 30-day
after same-day discharge after primary PCI.
Keywords: Early discharge, Primary percutaneous coronary intervention, Zwolle risk score, ST-segment elevation
myocardial infarction, Major adverse cardiac events

1. Introduction

I

nadequate blood supply to the myocardium
resulting from severe narrowing of the coronary
arteries, known as atherosclerotic cardiovascular
disease or coronary artery disease (CAD), remains
the major contributor to the increasing morbidity

and mortality all across the globe [1]. The acute
manifestation of the disease, known as acute coronary syndrome (ACS), comprises of ST-segment
elevation myocardial infarction (STEMI), NonSTEMI (NSTEMI), and unstable angina (UA).
Imbalance supply and demand of oxygen can cause
substantial and sustained ischaemia resulting in
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death of myocardiocytes which generally termed as
myocardial infarction (MI) [2]. Transmural
ischaemia in cases of STEMI involve full thickness
of the myocardium, while NSTEMI does not spread
to full thickness, hence early detection and restoration of blood ﬂow is crucial to minimize the infarct
size and preservation of myocardium [3,4]. Time is
crucial in the management of STEMI and various
initiatives have been taken to minimize the ischemic
time. In the current clinical practice guidelines, the
primary percutaneous coronary intervention (PCI)
within the 12 h window period, starting from time of
onset of symptoms, remains the recommended
reperfusion therapy [3,4].
A signiﬁcant improvements in the prognosis has
been witnessed for the STEMI patients in the recent
years, which can be attributed to the adoption of
evidence based medicines and therapies and signiﬁcant advancements it the treatment modalities.
However, rate of post- STEMI complications and
recurrent ischemia is still substantially high among
these patients [5e8]. Occurrence of severe, occasionally life-threatening, complications such as reinfarction, stent thrombosis, malignant arrhythmias,
heart failure, and other mechanical complications
are associated with STEMI [9]. This necessitates
coronary care unit monitoring of these patients for
at least 24e48 h. With the increasing number of
patients with CAD requiring extended post-procedure hospital care, identiﬁcation of low-risk patients has become crucial in whom early discharge
could be safe. Reduced post-procedure hospital stay
can be beneﬁcial for patients as well as it can have
substantial ﬁnancial implications for healthcare
systems of low and middle-income countries with
funding and resource constraints [10]. Safety and
feasibility of early discharge (within 48e72 h of
procedure) has been established by various studies
[11e14]. Also same-day discharge strategy showed
promising results with lower rate of major adverse
cardiac events after 30-days of the procedure [10].
A systematic evaluation of candidate patients for
decision making regarding early discharge is
important to optimize clinical outcomes of primary
PCI. Hence, Zwolle Risk Score (ZRS) was developed
to guide physicians’ decision making regarding
early discharge [15]. Its utility has been evaluated by
various studies for 72 h discharge [16e18], however;
performance of ZRS in same-day discharge strategy
for primary PCI has never been evaluated.

2. Objectives
Therefore, aim of this study was to evaluate the
clinical utility of ZRS for the same-day discharge
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strategy in patients with STEMI underwent primary
PCI at a tertiary care cardiac center of Karachi,
Pakistan.

3. Methods
This prospective observational cohort study is a
sub-group analysis of a previously reported study
by Shah JA et al. [10]. This study was conducted at a
tertiary care cardiac hospital of Karachi, Pakistan
between August 2019 and July 2020. Study included
consecutive patients with STEMI that were discharged to home by treating physician within in 24 h
(same-day) of primary PCI procedure. This study
was approved by the ethical review board of the
institution and consent for participation, and followup was taken from all the patients. A detailed descriptions of patient recruitment, management, and
evaluation criteria are presented elsewhere [10].
Patients with myocardial infarction complicated by
cardiogenic shock, atrioventricular (AV) block, or
history of prior cardiac surgery or intervention or
patients lost to follow-up at 30-day (3.4% (17)) [10]
were excluded from the study.
Along with demographic and clinical characteristics, described elsewhere [10], the Zwolle risk score
(ZRS) was calculated as per the scoring criteria
deﬁned by De Luca G et al. [15] based on age, Killip
class at presentation, total ischemic time (deﬁned as
symptom onset to device activation time), anterior
wall myocardial infarction (AWMI), pre-procedure
TIMI (Thrombolysis in Myocardial Infarction) ﬂow
grade, and number of diseased vessels. Patients were
categorized into high- and low-risk group based on
additive score; low-risk (3) and high-risk (4). All
patients were followed during 30-days post-procedure period, telephonic or physical, and major adverse
cardiac events (MACE) were noted which included
mortality, re-infarction, repeat revascularization, cerebrovascular events, any bleeding event, or unplanned hospitalization due to heart failure.
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IBM SPSS software version 21 was used for the
analysis of data. Appropriate frequency percentage
or mean ± standard deviation (SD)/median [interquartile range (IQR)] were calculated. Patients in lowand high-risk group were compared for demographic
and clinical characteristics and 30-day outcomes with
the help of appropriate independent sample t-test/
ManneWhitney U test and Chi-square test/Fisher's
exact test. The area under the curve (AUC) along with
its 95% conﬁdence interval (95%) were obtained for
ZRS to predict 30-day MACE using the receiver
operating characteristic (ROC) curve analysis. Crude
odds ratio (95% CI) for 30-day MACE and outcomes
were computed for high-risk group. P-value 0.05
was considered statistically signiﬁcant.

4. Results
A total of 487 same-day discharged patients were
included, out of which 83.2% (405) were male patients and mean age was 54.6 ± 10.87 years with
14.8% (72) elderly (>65 years) patients. More than
90% (444) of the patients were in Killip class I at
presentation. Mean ZRS was 2.34 ± 1.64 with 16.0%
(78) patients in high-risk group. Baseline characteristics, angiographic ﬁndings, procedural characteristics and post-procedure complications by highand low-risk groups are presented in Table 1.
Thirty-day MACE rate was observed to be 5.3%
(26), with a signiﬁcantly higher rate among high-risk
group as compared to low-risk group 12.8% (10) vs.
3.9% (16); p ¼ 0.004 respectively. High-risk group
had signiﬁcantly higher risk of 30-day MACE with
OR of 3.61 [1.57e8.29]. Similarly, risk of 30-day allcause mortality was higher among patients in highrisk group with OR of 5.6 [1.76e17.84] with 30-day
all-cause mortality rate of 7.7% (6) vs. 1.5% (6);
p ¼ 0.006 respectively. The 30-day major adverse
cardiac events rate stratiﬁed by low- and high-risk
groups are presented in Table 2.
The ROC of ZRS for prediction of 30-day MACE is
presented in Fig. 1. The AUC of ZRS for prediction
of 30-day MACE was found to be 0.67 [95% CI:
0.58e0.77], cut-off criteria of ZRS 4 for a high-risk
group had a sensitivity of 38.5% and speciﬁcity of
85.2% with AUC of 0.62 [95% CI: 0.5e0.74] for prediction of 30-day MACE.

5. Discussion
The aim of this study was to assess the utility of
the ZRS for the same-day discharge strategy after
primary PCI. ZRS showed moderate discriminating
power in identifying patients at higher risk of 30-day
MACE with AUC of 0.67 [0.58e0.77] and MACE rate
of 12.8% for the patients with ZRS of 4 (high-risk)

as against the 3.9% among patients with ZRS of 3
(low-risk).Safety of early discharge strategy
(48e72 h) after primary PCI with appropriately
planned follow-up has been well established for
low-risk patients in various studies. Zwolle risk
score is among the most commonly used systematic
assessment criteria for the identiﬁcation of low-risk
patients [19]. Some studies have also used NTproBNP (<200 pg/mL) [9] and CADILLAC risk score
2,28 for the identiﬁcation of candidate patients for
early discharge [20]. Although data are scarce
regarding same-day discharge strategy after primary PCI, only few studies so far have reported
favorable outcomes of same-day discharge strategy
in elective procedures [21e23] and only single
observational study so far has been reported for
primary PCI patients [11].
In a study conducted by Lim TW et al. [16] ZRS
has shown to have excellent discriminative capability in identifying patients at high-risk of 30-day
MACE and mortality among patients discharged
within 72 h of primary PCI with AUC of 0.79 [95%
CI: 0.68e0.90]. Tralh~
ao A et al. [17] further provided
evidence regarding applicability of ZRS for safe
discharge of patients within 72 h of primary PCI
with excellent AUC of 0.94 [95% CI: 0.91e0.97].
Schellings DA et al. [9] reported added advantage of
baseline N-terminal proebrain natriuretic peptide
(NT-proBNP) along with ZRS to optimize the accuracy of identiﬁcation of low-risk patients eligible for
early (within 72 h) discharge after primary PCI. The
combination of NT-proBNP 200 pg/mL and ZRS
<2 had the optimal accuracy for predicting low-risk
patients. In comparison to these earlier studies, the
performance of ZRS was observed more speciﬁc
(85.2%) than sensitive (38.5%) in identifying patients
at high-risk of 30-day MACE after discharge within
24 h of procedure with moderate discriminating
power (AUC ¼ 0.67 [95% CI: 0.58e0.77]).
Though same-day discharge strategy has substantial implications for patients as well as for the
healthcare system in optimizing and rationalizing
the use of resources, optimization of patient selection is also equally important to maintain the
effectiveness of primary PCI. The ZRS score,
otherwise established risk stratiﬁcation modality,
failed to attain optimal discriminating value to
detect the patients at higher risk of 30-day MACE
after primary PCI. Hence, risk stratiﬁcation tools,
such as ZRS need calibration for identiﬁcation of
candidate patients for the same-day discharge after
primary PCI. Echocardiographic and angiographic
ﬁndings along with careful clinical evaluation of
patients can provide additional power to the criteria
of categorization [17]. Additionally due importance

Table 1. Demographic and clinical characteristics, angiographic and procedural details, and post-procedure complications by high- and low-risk
group.
Characteristics

Total

Zwolle risk score (ZRS)
Low-risk (3)

Total (N)
487
409
Gender
Male
83.2% (405)
84.1% (344)
Female
16.8% (82)
15.9% (65)
Age (years)
54.6 ± 10.87
53.17 ± 10.42
 45 years
21.1% (103)
23.7% (97)
46e65 years
64.1% (312)
64.8% (265)
> 65 years
14.8% (72)
11.5% (47)
KILLIP Class
I
91.2% (444)
100% (409)
II
8.8% (43)
0% (0)
Duration of CP (minutes)
263 [150e450]
240 [150e450]
Type of myocardial infarction
Anterior
53.2% (259)
47.4% (194)
Inferior
40.5% (197)
45.7% (187)
Posterior
4.3% (21)
4.6% (19)
Lateral
2.1% (10)
2.2% (9)
Co-morbid conditions and risk factors
Hypertension
49.9% (243)
48.4% (198)
Diabetes
36.6% (178)
37.9% (155)
Family history of IHD
4.7% (23)
4.9% (20)
Smoking
33.9% (165)
33.7% (138)
Obesity
4.5% (22)
4.6% (19)
Access for the procedure
Radial
49.5% (241)
49.9% (204)
Femoral
50.5% (246)
50.1% (205)
Number of vessels involved
Single vessel disease
23% (112)
23% (94)
Two vessel disease
37.8% (184)
39.9% (163)
Three vessel disease
39.2% (191)
37.2% (152)
Culprit coronary artery
Left main
1.8% (9)
1.7% (7)
LAD
57.1% (278)
52.8% (216)
RCA
27.5% (134)
30.6% (125)
LCX
11.7% (57)
13% (53)
Ramus
1.2% (6)
1.5% (6)
Diagonal
0.6% (3)
0.5% (2)
Pre-procedural TIMI (thrombolysis in myocardial infarction) ﬂow grade
0
48.9% (238)
46.7% (191)
I
42.9% (209)
46% (188)
II
5.1% (25)
5.1% (21)
III
3.1% (15)
2.2% (9)
Post-procedural TIMI (thrombolysis in myocardial infarction) ﬂow grade
0
1% (5)
0.2% (1)
I
0.2% (1)
0% (0)
II
14.4% (69)
12% (48)
III
84.3% (403)
87.8% (352)
Post-procedure complication(s)
Total
0.82% (4)
0.73% (3)
Major bleeding
0.21% (1)
0.24% (1)
VT
0.21% (1)
0.24% (1)
Dissection
0.21% (1)
0% (0)
Other
0.21% (1)
0.24% (1)

P-value
High-risk (4)
78

-

78.2% (61)
21.8% (17)
62.08 ± 10.14
7.7% (6)
60.3% (47)
32.1% (25)

0.202
<0.001*
0.001*
0.444
<0.001*

44.9% (35)
55.1% (43)
300 [135e420]

0.006*

83.3% (65)
12.8% (10)
2.6% (2)
1.3% (1)

<0.001*
<0.001*
0.407
0.600

57.7% (45)
29.5% (23)
3.8% (3)
34.6% (27)
3.8% (3)

0.133
0.158
0.690
0.881
0.755

47.4% (37)
52.6% (41)

0.693

23.1% (18)
26.9% (21)
50% (39)

0.986
0.031*
0.033*

2.6% (2)
79.5% (62)
11.5% (9)
5.1% (4)
0% (0)
1.3% (1)

0.608
<0.001*
<0.001*
0.049*
0.282
0.412

60.3% (47)
26.9% (21)
5.1% (4)
7.7% (6)

0.028*
0.002*
0.998
0.01*

5.2% (4)
1.3% (1)
27.3% (21)
66.2% (51)

<0.001*
0.022*
<0.001*
<0.001*

1.28% (1)
0% (0)
0% (0)
1.28% (1)
0% (0)

0.504
e
e
e
e

0.299

*signiﬁcant at 5%.
IHD ¼ ischemic heart diseases, CP ¼ chest pain, RCA ¼ right coronary artery, LAD ¼ left anterior descending artery, LCx ¼ left
circumﬂex artery, VT ¼ ventricular tachycardia.
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Table 2. 30-day major adverse cardiac event stratiﬁed by low- and high-risk group.
Characteristics

N
MACE
All-cause death
Re-infarction
Bleeding events
Cerebrovascular events
Hospitalization for HF
Repeat-revascularization

Total

487
5.3%
2.5%
0.6%
0.6%
1.4%
0.4%
1.4%

Zwolle risk score (ZRS)

(26)
(12)
(3)
(3)
(7)
(2)
(7)

P-value

Low-risk (3)

High-risk (4)

409
3.9% (16)
1.5% (6)
0.5% (2)
0.7% (3)
1.5% (6)
0.5% (2)
1% (4)

78
12.8% (10)
7.7% (6)
1.3% (1)
0% (0)
1.3% (1)
0% (0)
3.8% (3)

e
0.004*
0.006*
0.408
>0.999
>0.999
>0.999
0.085

*signiﬁcant at 5%.
HF ¼ heart failure, MACE ¼ major adverse cardiac event.

MACE at 30-day after same-day (within 24 h)
discharge after primary PCI. Further large scale
randomized studies are needed for the calibration of
ZRS to optimize categorization of patients that can
potentially beneﬁt from the same-day discharge
after primary PCI.
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Fig. 1. Receiver operating characteristic of Zwolle risk score for prediction of 30-day major adverse cardiac events.

should be given to various patient related factors
such as ejection fraction, renal function, frailty score,
age, presence of arrhythmias, and hemodynamic
status to help prevent unnecessary discharge of
higher risk patients. Along with appropriate measures to improve cardiac rehabilitation, patient education, and drug titration as some researchers have
shown concern regarding these with the early
discharge strategy [24].
Even though this is ﬁrst study evaluating utility of
ZRS for the prediction of high-risk patients after
discharge within 24 h of primary PCI. However,
limitations of the study include single center
coverage, relatively small sample size, and nonrandomized study design. Hence, further large scale
randomized studies are needed to validate the use
of ZRS to facilitate physicians in clinical decision
making regarding same-day discharge.

6. Conclusion
The ZRS showed moderate discriminating potential in identifying patients with high-risk of
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